Short answer
ANI PHARMACEUTICALS INC (ANIP) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $266M (up 25.9% year over year) with net income of $25M.
Q2 2026 key financials · XBRL
- Revenue
- $266M
- +25.9% YoY · +12.0% QoQ
- Net income
- $25M
- +189.1% YoY · −16.2% QoQ
- Operating margin
- 15.2%
- EPS (diluted)
- $1.04
- +188.9% YoY · −18.8% QoQ
Source: XBRL data from the ANI PHARMACEUTICALS INC (ANIP) Q2 2026 10-Q on SEC EDGAR. USD.
ANI PHARMACEUTICALS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk factors provided in the submitted excerpt
- Executive Rule 10b5-1 plans for sales of up to 39,040 shares beginning August–September 2026
- Employee tax-withholding share transfers totaled 10,425 shares at $78.00 average
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ANI PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.